TY - JOUR TI - Bile-based liquid biopsy in cholangiocarcinoma: current evidence, clinical applications and future directions AU - Andrade, Rita AU - Oliveira, Rui Caetano AU - Martins, Maria Fátima AU - Ribeiro, Ilda Patrícia AU - Carreira, Isabel Maria AU - Tralhão, José Guilherme PY - 2026 JO - Exploration of Targeted Anti-tumor Therapy VL - 7 SP - 1002413 DO - 10.37349/etat.2027.1002413 UR - https://www.explorationpub.com/Journals/etat/Article/1002413 AB - Cholangiocarcinoma (CCA) is a heterogeneous and often late-diagnosed malignancy in which tissue acquisition, pathological confirmation, and molecular profiling remain clinically challenging. Precision oncology has increased the need for reliable tumour-derived molecular information, particularly when conventional cytology or biopsy is inconclusive or inadequate for next-generation sequencing (NGS). Bile has emerged as a candidate liquid biopsy matrix because it directly drains the biliary tree and may come into contact with malignant or premalignant biliary epithelium, potentially concentrating tumour-derived DNA, RNA, extracellular vesicles (EVs), proteins and metabolites at the site of disease rather than diluting them in the systemic circulation. Bile-derived cell-free DNA (cfDNA) and circulating tumour DNA (ctDNA) are the most mature biomarkers, with matched studies reporting somatic mutation detection in up to 70–71% of bile cfDNA samples compared with 10–54% in plasma, along with higher variant allele fractions and stronger concordance with tumour tissue. The most immediate clinical application is the evaluation of indeterminate biliary strictures, where an NGS-based bile cfDNA assay (Bilemut), evaluated in a mixed cohort of suspicious biliary strictures, achieved an overall sensitivity of 96.4% and a specificity of 69.2%, reaching 100% sensitivity in the 35 patients initially classified as having benign or indeterminate strictures, although this was a single-centre pilot cohort requiring independent validation. DNA methylation, non-coding RNAs, EVs, proteomic and lipidomic signatures are expanding the field beyond mutation detection, with integrated multi-omic approaches showing early promise for diagnosis and risk stratification. Translation to clinical practice remains limited by small cohorts, heterogeneous populations, variable sampling protocols, and the absence of prospective evidence that bile testing changes management or improves outcomes. Its most defensible role is additive rather than substitutive: bile adds molecular information from the local biliary compartment at the moment of an already indicated procedure, in patients in whom tissue is insufficient or non-diagnostic, and plasma is non-informative. ER -